Copyright Reports & Markets. All rights reserved.

Global Biosimilar Insulin Market Research Report 2020

Request for Sample of this report
Buy now

Table of Contents

    1 Biosimilar Insulin Market Overview

    • 1.1 Product Overview and Scope of Biosimilar Insulin
    • 1.2 Biosimilar Insulin Segment by Type
      • 1.2.1 Global Biosimilar Insulin Sales Growth Rate Comparison by Type (2021-2026)
      • 1.2.2 Rapid Acting Insulins
      • 1.2.3 Short Acting Insulins
      • 1.2.4 Intermediate Insulins
      • 1.2.5 Long Lasting Insulins
    • 1.3 Biosimilar Insulin Segment by Application
      • 1.3.1 Biosimilar Insulin Sales Comparison by Application: 2020 VS 2026
      • 1.3.2 Hospital
      • 1.3.3 Clinic
      • 1.3.4 Medical Center
    • 1.4 Global Biosimilar Insulin Market Size Estimates and Forecasts
      • 1.4.1 Global Biosimilar Insulin Revenue 2015-2026
      • 1.4.2 Global Biosimilar Insulin Sales 2015-2026
      • 1.4.3 Biosimilar Insulin Market Size by Region: 2020 Versus 2026

    2 Global Biosimilar Insulin Market Competition by Manufacturers

    • 2.1 Global Biosimilar Insulin Sales Market Share by Manufacturers (2015-2020)
    • 2.2 Global Biosimilar Insulin Revenue Share by Manufacturers (2015-2020)
    • 2.3 Global Biosimilar Insulin Average Price by Manufacturers (2015-2020)
    • 2.4 Manufacturers Biosimilar Insulin Manufacturing Sites, Area Served, Product Type
    • 2.5 Biosimilar Insulin Market Competitive Situation and Trends
      • 2.5.1 Biosimilar Insulin Market Concentration Rate
      • 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
      • 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
    • 2.7 Primary Interviews with Key Biosimilar Insulin Players (Opinion Leaders)

    3 Biosimilar Insulin Retrospective Market Scenario by Region

    • 3.1 Global Biosimilar Insulin Retrospective Market Scenario in Sales by Region: 2015-2020
    • 3.2 Global Biosimilar Insulin Retrospective Market Scenario in Revenue by Region: 2015-2020
    • 3.3 North America Biosimilar Insulin Market Facts & Figures by Country
      • 3.3.1 North America Biosimilar Insulin Sales by Country
      • 3.3.2 North America Biosimilar Insulin Sales by Country
      • 3.3.3 U.S.
      • 3.3.4 Canada
    • 3.4 Europe Biosimilar Insulin Market Facts & Figures by Country
      • 3.4.1 Europe Biosimilar Insulin Sales by Country
      • 3.4.2 Europe Biosimilar Insulin Sales by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Biosimilar Insulin Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Biosimilar Insulin Sales by Region
      • 3.5.2 Asia Pacific Biosimilar Insulin Sales by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
      • 3.5.12 Philippines
      • 3.5.13 Vietnam
    • 3.6 Latin America Biosimilar Insulin Market Facts & Figures by Country
      • 3.6.1 Latin America Biosimilar Insulin Sales by Country
      • 3.6.2 Latin America Biosimilar Insulin Sales by Country
      • 3.6.3 Mexico
      • 3.6.3 Brazil
      • 3.6.3 Argentina
    • 3.7 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Biosimilar Insulin Sales by Country
      • 3.7.2 Middle East and Africa Biosimilar Insulin Sales by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 U.A.E

    4 Global Biosimilar Insulin Historic Market Analysis by Type

    • 4.1 Global Biosimilar Insulin Sales Market Share by Type (2015-2020)
    • 4.2 Global Biosimilar Insulin Revenue Market Share by Type (2015-2020)
    • 4.3 Global Biosimilar Insulin Price Market Share by Type (2015-2020)
    • 4.4 Global Biosimilar Insulin Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

    5 Global Biosimilar Insulin Historic Market Analysis by Application

    • 5.1 Global Biosimilar Insulin Sales Market Share by Application (2015-2020)
    • 5.2 Global Biosimilar Insulin Revenue Market Share by Application (2015-2020)
    • 5.3 Global Biosimilar Insulin Price by Application (2015-2020)

    6 Company Profiles and Key Figures in Biosimilar Insulin Business

    • 6.1 Pfizer
      • 6.1.1 Corporation Information
      • 6.1.2 Pfizer Description, Business Overview and Total Revenue
      • 6.1.3 Pfizer Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.1.4 Pfizer Products Offered
      • 6.1.5 Pfizer Recent Development
    • 6.2 Biogenomics
      • 6.2.1 Biogenomics Biosimilar Insulin Production Sites and Area Served
      • 6.2.2 Biogenomics Description, Business Overview and Total Revenue
      • 6.2.3 Biogenomics Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.2.4 Biogenomics Products Offered
      • 6.2.5 Biogenomics Recent Development
    • 6.3 Eli Lilly
      • 6.3.1 Eli Lilly Biosimilar Insulin Production Sites and Area Served
      • 6.3.2 Eli Lilly Description, Business Overview and Total Revenue
      • 6.3.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.3.4 Eli Lilly Products Offered
      • 6.3.5 Eli Lilly Recent Development
    • 6.4 Gan&Lee Pharmaceuticals
      • 6.4.1 Gan&Lee Pharmaceuticals Biosimilar Insulin Production Sites and Area Served
      • 6.4.2 Gan&Lee Pharmaceuticals Description, Business Overview and Total Revenue
      • 6.4.3 Gan&Lee Pharmaceuticals Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.4.4 Gan&Lee Pharmaceuticals Products Offered
      • 6.4.5 Gan&Lee Pharmaceuticals Recent Development
    • 6.5 Geropharm
      • 6.5.1 Geropharm Biosimilar Insulin Production Sites and Area Served
      • 6.5.2 Geropharm Description, Business Overview and Total Revenue
      • 6.5.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.5.4 Geropharm Products Offered
      • 6.5.5 Geropharm Recent Development
    • 6.6 Julphar Gulf Pharmaceutical Industries
      • 6.6.1 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Production Sites and Area Served
      • 6.6.2 Julphar Gulf Pharmaceutical Industries Description, Business Overview and Total Revenue
      • 6.6.3 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.6.4 Julphar Gulf Pharmaceutical Industries Products Offered
      • 6.6.5 Julphar Gulf Pharmaceutical Industries Recent Development
    • 6.7 Paras Biopharmaceuticals
      • 6.6.1 Paras Biopharmaceuticals Biosimilar Insulin Production Sites and Area Served
      • 6.6.2 Paras Biopharmaceuticals Description, Business Overview and Total Revenue
      • 6.6.3 Paras Biopharmaceuticals Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.4.4 Paras Biopharmaceuticals Products Offered
      • 6.7.5 Paras Biopharmaceuticals Recent Development
    • 6.8 Samsung Bioepis
      • 6.8.1 Samsung Bioepis Biosimilar Insulin Production Sites and Area Served
      • 6.8.2 Samsung Bioepis Description, Business Overview and Total Revenue
      • 6.8.3 Samsung Bioepis Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.8.4 Samsung Bioepis Products Offered
      • 6.8.5 Samsung Bioepis Recent Development
    • 6.9 Sedico
      • 6.9.1 Sedico Biosimilar Insulin Production Sites and Area Served
      • 6.9.2 Sedico Description, Business Overview and Total Revenue
      • 6.9.3 Sedico Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.9.4 Sedico Products Offered
      • 6.9.5 Sedico Recent Development
    • 6.10 Wockhardt
      • 6.10.1 Wockhardt Biosimilar Insulin Production Sites and Area Served
      • 6.10.2 Wockhardt Description, Business Overview and Total Revenue
      • 6.10.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.10.4 Wockhardt Products Offered
      • 6.10.5 Wockhardt Recent Development
    • 6.11 Teva Pharmaceuticals
      • 6.11.1 Teva Pharmaceuticals Biosimilar Insulin Production Sites and Area Served
      • 6.11.2 Teva Pharmaceuticals Biosimilar Insulin Description, Business Overview and Total Revenue
      • 6.11.3 Teva Pharmaceuticals Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
      • 6.11.4 Teva Pharmaceuticals Products Offered
      • 6.11.5 Teva Pharmaceuticals Recent Development

    7 Biosimilar Insulin Manufacturing Cost Analysis

    • 7.1 Biosimilar Insulin Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Raw Materials Price Trend
      • 7.1.3 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Biosimilar Insulin
    • 7.4 Biosimilar Insulin Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Biosimilar Insulin Distributors List
    • 8.3 Biosimilar Insulin Customers

    9 Market Dynamics

    • 9.1 Market Trends
    • 9.2 Opportunities and Drivers
    • 9.3 Challenges
    • 9.4 Porter's Five Forces Analysis

    10 Global Market Forecast

    • 10.1 Global Biosimilar Insulin Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Biosimilar Insulin by Type (2021-2026)
      • 10.1.2 Global Forecasted Revenue of Biosimilar Insulin by Type (2021-2026)
    • 10.2 Biosimilar Insulin Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Biosimilar Insulin by Application (2021-2026)
      • 10.2.2 Global Forecasted Revenue of Biosimilar Insulin by Application (2021-2026)
    • 10.3 Biosimilar Insulin Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Biosimilar Insulin by Region (2021-2026)
      • 10.3.2 Global Forecasted Revenue of Biosimilar Insulin by Region (2021-2026)
    • 10.4 North America Biosimilar Insulin Estimates and Projections (2021-2026)
    • 10.5 Europe Biosimilar Insulin Estimates and Projections (2021-2026)
    • 10.6 Asia Pacific Biosimilar Insulin Estimates and Projections (2021-2026)
    • 10.7 Latin America Biosimilar Insulin Estimates and Projections (2021-2026)
    • 10.8 Middle East and Africa Biosimilar Insulin Estimates and Projections (2021-2026)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      The global Biosimilar Insulin market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.
      This report focuses on Biosimilar Insulin volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Biosimilar Insulin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
      Market Segment Analysis
      The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
      Segment by Type, the Biosimilar Insulin market is segmented into
      Rapid Acting Insulins
      Short Acting Insulins
      Intermediate Insulins
      Long Lasting Insulins

      Segment by Application
      Hospital
      Clinic
      Medical Center

      Global Biosimilar Insulin Market: Regional Analysis
      The Biosimilar Insulin market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
      The key regions covered in the Biosimilar Insulin market report are:
      North America
      U.S.
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      Taiwan
      Indonesia
      Thailand
      Malaysia
      Philippines
      Vietnam
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      U.A.E
      Global Biosimilar Insulin Market: Competitive Analysis
      This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
      The major players in global Biosimilar Insulin market include:
      Pfizer
      Biogenomics
      Eli Lilly
      Gan&Lee Pharmaceuticals
      Geropharm
      Julphar Gulf Pharmaceutical Industries
      Paras Biopharmaceuticals
      Samsung Bioepis
      Sedico
      Wockhardt
      Teva Pharmaceuticals

      Buy now